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Over 18 million disease cases and half a million deaths worldwide are estimated to be caused annually by
Group A Streptococcus. A vaccine to prevent GAS disease is urgently needed. SpyCEP (Streptococcus pyoge-
nes Cell-Envelope Proteinase) is a surface-exposed serine protease that inactivates chemokines, impairing
neutrophil recruitment and bacterial clearance, and has shown promising immunogenicity in preclinical
models. Although SpyCEP structure has been partially characterized, a more complete and higher resolution
understanding of its antigenic features would be desirable prior to large scale manufacturing. To address
these gaps and facilitate development of this globally important vaccine, we performed immunogenicity
studies with a safety-engineered SpyCEP mutant, and comprehensively characterized its structure by com-
bining X-ray crystallography, NMR spectroscopy and molecular dynamics simulations. We found that the
catalytically-inactive SpyCEP antigen conferred protection similar to wild-type SpyCEP in a mouse infection
model. Further, a new higher-resolution crystal structure of the inactive SpyCEP mutant provided new
insights into this large chemokine protease comprising nine domains derived from two non-covalently
linked fragments. NMR spectroscopy and molecular simulation analyses revealed conformational flexibility
that is likely important for optimal substrate recognition and overall function. These combined immuno-
genicity and structural data demonstrate that the full-length SpyCEP inactive mutant is a strong candidate
human vaccine antigen. These findings show how a multi-disciplinary study was used to overcome obsta-
cles in the development of a GAS vaccine, an approach applicable to other future vaccine programs.
Moreover, the information provided may also facilitate the structure-based discovery of small-molecule
therapeutics targeting SpyCEP protease inhibition.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
Streptococcus pyogenes (Group A streptococcus; GAS) is an
important human pathogen, responsible for a significant anddiverse global disease burden from mild conditions such as
impetigo and pharyngitis, through to life-threatening conditions
such as acute rheumatic fever, rheumatic heart disease, strepto-
coccal toxic shock syndrome and necrotising fasciitis [1]. The glo-
bal disease burden attributed to S. pyogenes infection is estimated
to be over 600 million cases annually, of which 18 million cases
can be attributed to severe S. pyogenes infection, with approxi-
mately 1.8 million new cases, and over 517,000 deaths reported
annually [2,3].
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inactivate the innate immune response [4]. Neutrophil recruitment
and activation, mediated by the ELR+ group of chemokines and
vital for bacterial clearance, is impaired in lethal soft-tissue S. pyo-
genes infections [5,6]. The S. pyogenes Cell Envelope Proteinase
(SpyCEP) is a highly conserved surface-exposed serine protease
that cleaves and inactivates all ELR+ chemokines (containing the
N-terminal glutamate leucine arginine motif), notably CXCL8
[7,8], mediating evasion of immune system clearance strategies
and systemic dissemination [9]. High level expression of SpyCEP
correlates with disease severity and is indicative of a vital role in
invasive S. pyogenes infection [8,10].
SpyCEP is a 180 kDa heterodimer made of two non-covalently
linked polypeptides derived from the full-length protein by an
intramolecular autocatalytic processing event [11]. The N- and C-
terminal fragments are 30 and 150 kDa respectively, and both con-
tribute residues to the catalytic triad (D151 from the N-terminal
fragment, H279 and S617 from the C-terminal fragment). The
two components of SpyCEP can also be produced separately and
reconstituted to generate the active enzyme [11,12]. Recently-
determined crystal structures of SpyCEP, refined at only 2.8–
3.1 Å resolution unveiled a modular protease that comprises nine
distinct domains with the first five domains vital for catalytic activ-
ity [13]. Although a near full-length ectodomain SpyCEP construct
was used for crystallization, several parts of the protein remained
structurally uncharacterized, including the N-terminal region 34–
114, the C-terminal region 1575–1613, and a more central region
(214–272) containing the site of auto-cleavage.
Although a global priority, there is no licensed vaccine against S.
pyogenes. Systematic proteomic analysis of S. pyogenes surface
antigens identified SpyCEP as a leading vaccine candidate, confer-
ring protection in a mouse challenge model after immunisation
with a recombinant SpyCEP N-terminal fragment [14]. An
immunoproteomic screen also identified SpyCEP as a leading target
of an affinity-purified, protective anti-S. pyogenes human
immunoglobulin preparation [15]. Vaccine-induced protection
mediated by SpyCEP fragments has been observed in a various pre-
clinical models, when used alone [16–18] or in combination with
other antigens [19–21]. SpyCEP is surface-exposed, anchored to
the bacterial cell wall and highly conserved between isolates
[22], underlining its potential as a vaccine candidate. Vaccine-
induced protection may, at least partially, reside in the ability of
anti-SpyCEP antibodies to neutralise SpyCEP-mediated CXCL8
cleavage and reduce systemic dissemination of streptococci [23].
Binding of SpyCEP-specific IgG to the bacterial cell surface could
also enhance complement-mediated phagocytic killing, further
contributing to protection.
Detailed knowledge of antigen structure enables setup of appro-
priate in-process quality controls building confidence during vac-
cine manufacturing, and also provides an opportunity to fully
employ structural vaccinology methods, by rationally redesigning
antigensandepitopes to improve safety andefficacy [24,25].Despite
the first glimpse into the SpyCEP structure [13], key questions
regarding substrate interactions and dynamic properties remain.
Although there is clear potential for SpyCEP to advance S. pyogenes
vaccine development, structure-based antigen design has played a
limited role in S. pyogenes research to date; most studies have used
heavily truncated SpyCEP constructs [16,17,26,27] or the wild-type
recombinant protein with intact protease activity [19].
Inactivation of the SpyCEP protease activity by amino acid sub-
stitution of the residues constituting its catalytic triad should
result in a safer single polypeptide vaccine antigen. However, an
immature (proprotein) form of a catalytically-inactive SpyCEP
may conceivably have altered structure and immunogenticity,
and the ability of such a full-length mutated antigen to confer pro-
tection against S. pyogenes has not been reported previously. In thepresent study we set out to evaluate the ability of a full length Spy-
CEP protease-inactive mutant to confer vaccine-induced immunity,
and to elucidate the structure and dynamics of this mutated vac-
cine antigen. We present the crystal structure of this novel inactive
SpyCEP mutant and combine this with solution NMR and molecu-
lar dynamics data that shed further light on the mechanism of
action of this chemokine protease and provide a framework for
future structural vaccinology efforts.2. Materials and methods
2.1. Expression and purification of SpyCEP N- and C-terminal domains
The SpyCEP34-1613 (D151A S617A) double mutant used in
immunogenicity and crystallization experiments was previously
cloned into pET-24b (Novagen) and purified from E. coli BL21
(DE3) (New England Biolabs) soluble extracts as described [11].
SpyCEP N- (A34-Q244) and C-terminal (S245-A1613) domains
were cloned into pET-28b (Novagen) utilising N- and C-terminal
hexa-histidine tags, respectively. These constructs encompass the
M1 strain SpyCEP ectodomain, excluding the leader peptide and
LPXTG motif (Fig. S1). Two inactive mutants (D151A and S617A)
were produced with the Q5 Site-Directed Mutagenesis Kit (New
England Biolabs) and verified by DNA sequencing. [U-15N, 13C]-
labelled SpyCEP245-1613 S617A or [U-15N]-labelled SpyCEP34-244
D151A and [U-15N]-labelled SpyCEP245-1613 S617A were produced
by growing transformed E. coli BL21 (DE3) cells (New England Bio-
labs) in M9 enriched medium containing 50 lg/ml kanamycin and
supplemented with 15NH4Cl (1 g/L) and 12C or 13C-glucose (2 g/L).
The cultures were grown at 37 C until an optical density at 600 nm
of 0.8 was reached. Protein expression was induced by addition of
0.5 mM isopropyl b-D-thiogalactopyranoside (IPTG) and the cul-
tures were grown at 18 C overnight. The cells were harvested by
centrifugation at 5000g, 4 C for 15 min. [U-15N, 13C, 2D]-labelled
SpyCEP34-244 D151A was expressed in Silantes OD2 CDN rich media
under the same conditions.
The constructs were purified by resuspending cellular pellets in
buffer A (50mMNa phosphate pH 7.4, 500mMNaCl, 20mM imida-
zole) supplemented with a Complete, EDTA-free protease inhibitor
tablet (Roche). The cells were disrupted by sonication and the lysate
was clarified by centrifugation at 38,000g, 4 C for 45 min. The clar-
ified lysate was loaded onto a 5 ml HisTrap FF crude column (GE
Healthcare) equilibrated with buffer A and eluted with a gradient
of 20–500mM imidazole. Fractions of interest were identified using
SDS–PAGE, pooled, concentrated and recombined in a 1:1.5 M ratio
(SpyCEP245-1613 S617A:SpyCEP34-244 D151A). Final separation was
achievedwith a Superdex 200 16/600 column (GEHealthcare) equi-
librated with 20 mM MES pH 6.5, 150 mM NaCl. Adequate separa-
tion, observed by SDS–PAGE, was achieved. Homogeneity was
assessed by native PAGE with the recombined sample migrating as
one distinct band. N-terminal truncations (104–244, 109–244,
114–244, 116–244 and 121–244) and the C-terminal truncation
(245–1578) were produced with the Q5 Site-Directed Mutagenesis
Kit and verified by DNA sequencing. All mutants were expressed in
the active form or with the D151A and S617A mutations.2.2. Protein crystallization, structure determination, refinement and
validation
Purified SpyCEP34-1613 (D151A S617A) protein was concentrated
to 5 mg/ml and used for crystallization trials with a Crystal Gry-
phon liquid handling robot (Art Robbins Instruments) by mixing
equal volumes (200 nl) of SpyCEP sample with crystallization
reservoir solution. Crystals were obtained after roughly 2 weeks
of incubation at room temperature (20 C), in a condition contain-
Table 1
Data collection and refinement statistics.
Uniprot ID/Construct Q9A180/SpyCEP D151A–S617A
PDB code 6VJB
Wavelength 0.93940
Resolution range (Å)* 89.01–2.24 (2.29–2.24)
Space group C 1 2 1
Cell dimensions
a, b, c (Å) 140.5, 121.75, 106.64
a, b, c () 90, 111.78, 90
Total reflections 170,606 (7476)
Unique reflections 76,948 (3691)
Multiplicity 2.2 (2.0)
Completeness (%) 96.6 (78.6)
Mean I/sigma (I) 3.41 (1.6)





Reflections used in refinement 76,782 (6488)
Reflections used for R-free 3901 (326)
Rwork 0.193 (0.423)
Rfree 0.244 (0.515)






Ramachandran favored (%) 94.55
Ramachandran allowed (%) 5.45
Ramachandran outliers (%) 0
Rotamer outliers (%) 4.45
Clashscore 3.7
Average B-factor 52.0
*Highest resolution shell is shown in parenthesis.
Rsym = Rhkl Ri|Ii(hkl)  hI(hkl)i|/Rhkl Ri Ii(hkl).
Rwork = R||F(obs)|  |F(calc)||/R|F(obs)|.
Rfree = as for Rwork, but calculated for 5.0% of the total reflections that were chosen at
random and omitted from refinement.
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tals were then mounted in cryo-loops, soaked in 20% ethyelene gly-
col (cryo-protectant) and stored in liquid nitrogen prior to X-ray
data collection, which was performed at cryogenic temperatures
(100 K) on beamline ID14-4 at the European Synchrotron Radiation
Facility (ESRF), Grenoble, France. Data were processed using XDS
[28] and other programs from the CCP4 [29] and PHENIX suites
[30] revealing that crystals belonged to the monoclinic C2 space
group and with cell parameters: a = 89.01 Å, b = 121.75 Å, c = 10
6.64 Å, and b = 111.78. A Matthews coefficient of 2.38 Å3/Da, com-
patible with a solvent content of 48%, suggested the presence of
one monomer in the asymmetric unit, as also confirmed by the
molecular replacement (PHASER, [31]) solution obtained using
coordinates from PDB 5XYR (crystal structure of SpyCEP from
Streptococcus pyogenes strain JS95) as the search model. Manual
model building and refinement were performed with Coot [32],
BUSTER [33] and REFMAC5 [34] respectively, while the final model
was inspected and validated using Molprobity [35]. Statistics for
structure solution and refinement are reported in Table 1
(pdb:6VJB). Figures of structures were generated using the molec-
ular graphic software Pymol (PyMOL Molecular Graphics System,
version 2.1; Schrödinger, LLC; http://www.pymol.org).
2.3. Assessment of SpyCEP immune responses in mice
Animal studies were conducted according to Italian Legislative
Decree 116/1992 guidelines and approved by the internal Animal
Welfare Body and the Italian Ministry of Health. Eight 5 week-
old female CD1 mice were vaccinated intraperitoneally with 6 mg
of SpyCEP34-1613 (D151A S617A) formulated in Alum. Sera collected
two weeks after the second immunization and diluted 1:100,
1:4000 and 1:160000 in PBS containing 0.05% Tween 20 and 0.1%
BSA were analyzed by ELISA for anti-SpyCEP total IgG content
using SpyCEP34-1613 (D151A S617A) as plate coating antigen (at
the concentration of 2 mg/ml in carbonate buffer). Pre-immune
and post-2nd immunization sera were also tested in a CXCL8 cleav-
age ELISA assay [11] to evaluate their ability to block SpyCEP pro-
teolytic activity. For in vivo protection experiments, groups of eight
mice receiving three 20 mg vaccine doses were infected intranasally
with GASM1 strain 3348 on day 42 [19]. Mice were monitored on a
daily basis for 1 week after treatment and euthanized when they
exhibited defined humane endpoints that had been pre-
established for the study in agreement with internal Animal Wel-
fare Policies. Animals Fisher’s exact test was used for data statisti-
cal analysis.
2.4. NMR spectroscopy
All spectra were recorded on a Bruker Avance III HD 800 MHz or
Bruker Avance III HD 950 equipped with triple-resonance cry-
oprobe. Spectral assignment of [U-15N, 13C, 2D]-labelled SpyCEP34-
244 D151A complexed with unlabelled SpyCEP245-1613 S617A was
performed at 60 lM in 20 mM MES pH 6.5, 150 mM NaCl, 10%
D2O. The assignment covers 73 of the first 90 residues of the N-
terminal domain. Spectral assignment of [U-15N, 13C]-labelled
SpyCEP245-1613 S617A complexed with unlabelled SpyCEP34-244
D151A was performed at 50 lM in 20 mM MES pH 6.5, 150 mM
NaCl, 10% D2O. The assignment covers the last 39 residues of the
C-terminal domain. HN(CO)CACB [36] and HNCACB [37] triple res-
onance spectra were acquired at 283 K and at 1H frequency of 800
and 950 MHz.
Spectra were processed with NMRPipe [38] and analysed using
CCPN Analysis version 2.4 [39]. Secondary chemical shifts were cal-
culated with POTENCI [40], ncIDP [41] and the protocol of Kjaer-
gaard et al. [42,43]. Secondary structure propensity was
calculated with ncSPC [41].2.5. CXCL8 cleavage assay
Kinetic parameters of CXCL8 cleavage by SpyCEP were obtained
using the Human IL-8/CXCL8 DuoSet ELISA kit (R&D Systems).
Clear 96-well microplates (R&D Systems) were coated with capture
antibody and incubated overnight at room temperature. Plates
were washed three times with 400 ml 0.05% Tween in PBS using a
Wellwash Microplate Washer (Thermo-Fisher). Wells were
blocked with 300 ml 1% BSA in PBS for 2 h before being re-
washed and loaded with 100 ml of prepared samples or CXCL8 stan-
dards for 2 h at room temperature. Standards were loaded in a 1:2
serial dilution from concentration 2000 pg/ml to 15.625 pg/ml. The
wells were rewashed and incubated with detection antibody for
2 h at room temperature. The wells were rewashed and incubated
with 100 ml Streptavidin–HRP for 20 min before being washed for a
final time and incubated with 100 ml Substrate Solution. The reac-
tion was stopped with the addition of 50 ml 1 M H2S04 and optical
density readings were obtained at 450 nm and 540 nm on a BMG
FLUOstar Omega plate reader.
The assay was performed with SpyCEP245-1613 or SpyCEP245-1578
complexed with SpyCEP34-244 and Human CXCL8 was obtained
from R&D Systems. Cleavage was examined using varying concen-
trations of CXCL8 (3–86 nM) incubated with 50 pM SpyCEP at 37 C
for 5 min and halted with 1 mg/ml Pefabloc SC plus (Sigma-
Aldrich). Intact CXCL8 levels were measured using a CXCL8 stan-
dard curve, according to the manufacturer’s protocols. The rate of
reaction was calculated as follows ([CXCL8]t=0  [CXCL8]t=5)/time.
The Vmax, kcat and Km were determined with Prism 7.05
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control was a saturating concentration of CXCL8.
2.6. Molecular dynamics simulations
Atomistic simulationswere run using the Gromacs 4.6.7 package
[44] (www.gromacs.org)with theGROMOS53a6 forcefield [45]. The
X-ray structure determined herein was used as the starting model,
and crystallographic Ca2+ ions were retained. The system was sol-
vated using the SPCwatermodel, and ionswere added to give a neu-
tral systemwith a final NaCl concentration of 0.15 Mwith an initial
box size of 13  13  13 nm. Periodic boundary conditions were
applied, with a simulation time step of 2 fs. Equilibration runs were
performed with duration of 1 ns and a time step of 2 fs. The protein
backbone was restrained, pressure was coupled at 1 bar using the
Berendsen barostat [46], and temperature was maintained at
310 K using a V-rescale thermostat [47] with a coupling constant
of 0.1 ps. For the 100-ns production runs, the pressure was con-
trolled at 1 bar through coupling to a Parrinello–Rahman barostat
[48] with a coupling constant of 1 ps. Particle Mesh Ewald was used
for long-range electrostatics [49] and the LINCS algorithmwas used
to constrain covalent bond length [50].3. Results and discussion
3.1. Catalytically-inactive SpyCEP(D151A, S617A) double mutant
elicits functional antibodies and confers protection in a mouse model
of invasive disease
Since an active protease may be considered a safety risk as a
human vaccine antigen, we evaluated the potential of a
genetically-engineered inactivated form of full-length SpyCEP to
act as a vaccine candidate (Fig. 1A). CD1 mice immunized with
the SpyCEP34-1613 (D151A, S617A) double mutant 170 kDa
polypeptide mounted a rapid serological response to the antigen
(Fig. 1B). We chose this double mutant of the catalytic triad as pre-
vious work had demonstrated that these mutations had minimal
effect on structure while rendering the enzyme not only catalyti-
cally inactive but able to form a fully folded enzyme [11]. The
immune sera provided dose-dependent inhibition of CXCL8 cleav-
age by wild-type SpyCEP (Fig. 1C, D). The geometric mean concen-
tration of sera able to reduce 50% of CXCL8 cleavage (IC50) was 2
logs higher after two vaccine doses compared to pre-immune sera
(Fig. 1C, D). The capacity of the SpyCEP34-1613 (D151A, S617A) dou-
ble mutant to mediate protection against M1T1 GAS intranasal
challenge was evaluated in mice receiving three vaccine doses over
42 day, or adjuvant alone as control. Significant levels of protection
were achieved for the vaccinated group compared to the negative
control (Fig. 1E). Together, these data show that the catalytically-
inactive SpyCEP double mutant can confer protection similar to
that reported previously [16–18], and that the mechanism of
vaccine-induced protection at least partially involves inhibition
of the natural SpyCEP-mediated chemokine inactivation process.
These findings suggest that the SpyCEP double-mutant is a valid
candidate for human vaccine development.
3.2. Crystal structure of SpyCEP(D151A, S617A)
We next completed the structure determination of the full
length SpyCEP vaccine construct. Extensive screening using crys-
tals suitable for X-ray diffraction ultimately yielded a novel struc-
ture of the full-length ectodomain harbouring the double mutation
in the active site, SpyCEP(D151A, S617A) [11], at 2.2 Å resolution, a
notable improvement on the resolution of the three previouslyreported structures [13]. A series of additional SpyCEP constructs
were expressed in and purified from Escherichia coli and subjected
to crystallization screens; N- and C-terminal truncations were cre-
ated based on the related C5a peptidase structure (excluding resi-
dues 1132 onwards) and some predicted disorder within residues
33–112 [51,52]. Attempts to optimise microcrystals for the trun-
cated constructs failed to yield improved crystals, suggesting that
the regions removed contain important features for structure or
stability, or mediate crystal contacts. A complete diffraction data
set to 3.3 Å resolution was collected previously [53], however past
attempts to solve the structure using molecular replacement with
existing structures of related proteases or by single-wavelength
anomalous dispersion (SAD) failed [53]. Further crystal optimiza-
tion and the availability of a recent X-ray structure of wild-type
SpyCEP and of a different catalytically inactive mutant (H279A,
S617A) [13] allowed us find a positive molecular replacement solu-
tion for our SpyCEP diffraction data. The X-ray data collection and
refinement statistics are summarized in Table 1.
The domain architecture of the SpyCEP(D151A, S617A) mutant
matches that observed in the published SpyCEP structures [13],
as expected, with nine distinct folded domains (D1–D9; Fig. 2). A
search of the protein data bank (PDB) using the DALI program
[54] revealed that the overall structure is most similar to that of
wild-type SpyCEP (pdb:5XYR), with a root mean square deviation
(RMSD) of 1.4 Å, obtained by superposing with 1248 equivalent
Ca atoms. The entire protease domain (D1) encompasses L119-
G689 and is located at the mature N terminus. It is interrupted
by an insertion domain (D2) between K420-N574 that is termed
the protease-associated (PA) domain. The core protease domain
belongs to the canonical subtilisin family with RMSDs in the range
of 1.9–2.0 Å over available subtilisin Carlsberg structures.
The next three domains of SpyCEP (D3:L690-F820, D4:E821-
D1016 and D5:R1017-E1146) are fibronectin-like domains, com-
prising a core b-sandwich with a Fibronectin Type III fold. An
extensive interdomain interface locks the relative position of the
protease and the first of the fibronectin domains (Fn1). The inter
b-strand regions of D4 and D5 contain elaborate loops and sec-
ondary structure elements, which facilitate interdomain contacts
and maintain their relative orientations. This whole element
(D1–D5) appears to be rigid as the same arrangement of the first
three fibronectin domains is also present in the C5a peptidases
from S. pyogenes and S. agalactiae [51,52] (RMSD 3.2 Å over 799
Ca atoms), and in this context could provide a rigid stalk to project
the protease machinery (~100 Å) from the C-terminal cell wall
anchor (Fig. 2C), presumably enhancing its functionality.
SpyCEP is significantly larger than the C5a peptidase and has an
additional four domains (D6:T1147-K1286; D7:K1287-K1396; D8:
D1397-M1489; D9:L1490-A1578) before the linkage to the cell
wall. D6 also belongs to the Fn Type III family, whereas the final
three domains (D7–D9) are similar to immunoglobin-like (Ig) folds,
but adopt the reversed strand order and are therefore termed
reversed Ig-like domains. These are commonly seen in sortase-
assembled pilin domains from Gram positive bacteria [55], where
they perform a role in host discrimination and cell adhesion.
Surprisingly, the two C-terminal domains (D8 and D9) in Spy-
CEP coil back on the structure and contact the protease domain
(Fig. 2B), an interaction that might retain this distal protease
domain proximal to the cell wall. Furthermore, three tightly bound
calcium ions present within the interfacial regions of D4–D7
(Fig. 2A) also appear to stabilise the overall architecture of SpyCEP.
Calcium regulation is a feature often seen in the related cell envel-
ope proteases of lactic acid bacteria, for example PrtS in S. ther-
mophilus [56]. It is therefore conceivable that host environmental
and signalling events that result in changes in local calcium con-
centrations, may facilitate a conformational switch from con-
Fig. 1. Immunogenicity and Protective activity of SpyCEP(D151A, S617A). (A) Domain architecture (B). Eight 5 weeks old female CD1 mice were vaccinated intraperitoneally
with 200 ml of a formulation containing 6 mg of antigen and 2 mg/mL of Alum. Mice were immunized at study day 0 and 28. Approximately 100 ml bleeds (50 ml serum) were
collected at day 1 (pooled sera). Final bleed was performed 2 weeks after the second immunization (sera maintained single) and mice were euthanized. Sera were analyzed
by ELISA for anti-SpyCEP total IgG content. (C) Sera were tested in the IL-8/CXCL8 cleavage assay to evaluate their ability to block native SpyCEP proteolytic activity. The
concentration of serum able to reduce of 50% the cleavage of CXCL8 is reported in the graph as IC50 value. (D) For pre immune serum and one selected post-2 serum
(highlighted in red in panel C), the amount of uncut CXCL8 observed at each serum dilution tested is reported. (E) Five week old female CD1 mice were immunized
intraperitoneally on days 0, 21 and 35 with 20 mg of SpyCEP (D151A, S617A) formulated in Alum or with Alum only as negative control. Mice were infected intranasally with
GAS M1 strain 3348 on day 42 and survival was monitored for 6 days. Fisher’s exact test was used for statistical analysis. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
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thereby facilitating enhanced presentation of the protease domain,
akin to the unbending of integrins [57].
3.3. SpyCEP contains N- and C-terminal intrinsically disordered
regions
The functional SpyCEP heterodimer is considered to span resi-
dues 34–1613, excluding the signal peptide (residues 1–33) and
the LPXTG cell wall-anchoring motif (residues 1614-1647)
[13,53]. However, electron density was only observed for residues
116–1574 of the ectodomain (MW ~160 kDa) in all SpyCEP crystal
structures, with residues 34–115 and 1575–1613 remaining
uncharacterized. IUPRED analysis predicts that these missing
regions are disordered [58]. Moreover, a recombinant N-terminal
fragment of SpyCEP spanning residues 31–245 was previously
studied by CD spectroscopy and indicated the presence of a ran-
dom coil denatured protein [11]. To shed light on these observa-
tions experimentally, we used solution NMR to explore theseterminal regions and assess their structural propensity, dynamics
and expose undetermined functional roles.
The ability to produce a heterodimeric version of catalytically
inactive SpyCEP provides an opportunity to study each domain
independently while in complex with an unlabelled complemen-
tary domain. Furthermore, any highly flexible regions should be
observable with standard heteronuclear NMRmethodology despite
the large overall molecular weight. The core structured unit of Spy-
CEP with a molecular mass of >160 kDa would not be observable in
non-TROSY NMR approaches due to its slow rotational tumbling in
solution.
(1H, 15N) HSQC spectra of uniformly [U-15N]-labelled SpyCEP34-
244 D151A and [U-15N]-labelled SpyCEP245-1613 S617A in complex
with their complementary unlabelled subunits exhibited narrow
proton chemical shift dispersion, which indicated the presence of
significant disorder within these regions. Also, the fact that these
regions were observed in NMR spectra indicated extensive dynam-
ics on a pico- to nano-second timescale [59] (Fig. 3). Notwithstand-
ing the large size of the SpyCEP heterodimer, 81 and 45 peaks were
Fig. 2. Structure of SpyCEP(D151A, S617A). (A) Cartoon representation of the structure of SpyCEP(D151A, S617A) in two orthogonal orientations. Domains are coloured
according to Fig. 1A and termini are indicated. (B) Cartoon representation of the superposition of the structure of C5a peptidase (pdb:1xf1 or 3eif; colored in grey) on the the
first 5 domains of SpyCEP(D151A, S617A). Schematic representation of the relative position of the domains and the cell wall anchor isshown on the left. (C) Superposition of
the structure of C5a peptidase (colored in grey) on SpyCEP(D151AS617A) with domains D5–D9 shown in surface representation. Schematic representation of the relative
position of the domains and the cell wall anchor is shown on the left.
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A triple-resonance backbone resonance assignment of the 13Ca,
13Cb, 1HN and 15N nuclei was performed at 283 K to determine
the sequence context of the disorder (Fig. 3). The N- and C-
terminal assignments map to residues spanning 34–113 and
1578–1613 of the SpyCEP ectodomain, respectively. These assign-
ments highlight the high degree of conformational flexibility expe-
rienced by both regions within the context of full-length SpyCEP,and likely explain the absence of electron density for these regions
in any of the crystal structures determined to date.
Secondary chemical shifts, the difference between experimen-
tally derived chemical shifts and residue-specific random coil
chemical shifts, are an invaluable tool to detect transient and
short-ranged secondary structure within intrinsically disordered
proteins. Secondary chemical shifts derived from 13C backbone
nuclei are sensitive reporters of secondary structure, with 13Ca
Fig. 3. Assigned NMR spectra of SpyCEP. 1H, 15N-HSQC spectra and assignment of (A) [U-15N]-labelled SpyCEP34-244 D151A complexed with unlabelled SpyCEP245-1613 S617A,
(B) [U-15N]-labelled SpyCEP245-1613 S617A complexed with unlabelled SpyCEP34-244 D151A. The N-terminal assignment (left) covers residues 34–113 of the SpyCEP
ectodomain. The C-terminal assignment (right) covers residues 1578–1613 of the SpyCEP ectodomain.
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values) propensity, while 13Cb chemical shifts exhibit the inverse
relationship [60]. 13Ca and 13Cb secondary chemical shifts were cal-
culated for SpyCEP resonance assignments [42,43] (Fig. 4). Resi-
dues 47–50, 71–82 and 99–107 exhibited pronounced 13Ca
secondary shifts and negative 13Cb shifts, indicating a persistent
helicity in the N-terminal disordered region. Secondary chemical
shifts calculated for the C-terminal disordered region are feature-
less until residue 1608, where a helical propensity is observed in
6 residues immediately prior to the site of membrane association
(Fig. S2). These data indicate that the N-terminal intrinsically dis-
ordered region (IDR) displays significant helical propensity, which
is likely to be important for the secretion of active SpyCEP and to
guide the folding process. In contrast, the C-terminal IDR exhibits
little secondary structure propensity and is therefore completely
unstructured except at the very C-terminus, which is recognised
by the sortase anchoring machinery.
N- and C-terminal domain truncations were designed to assess
the role of disorder on the SpyCEP34-1613 heterodimer, utilising
backbone assignment data and sequence alignment with close rel-
atives from other Streptococcus species. N-terminal truncations
were unstable and could not effectively complex with SpyCEP245-
1613. A C-terminal truncation, SpyCEP245-1578, expressed at a higherlevel than SpyCEP245-1613 and was reconstituted with SpyCEP34-244
to generate a stable dimer. The catalytic activity of this new con-
struct SpyCEP34-1578 was compared with SpyCEP34-1613 to deter-
mine the relevance of C-terminal disorder to enzyme activity.
SpyCEP mediated CXCL8 degradation was assessed with an
enzyme-linked immunosorbent assay (ELISA) (Fig. S3). KM values
were consistent between the two SpyCEP versions, suggesting C-
terminal disorder beyond D9 has little impact on CXCL8 binding
or catalytic activity. However, SpyCEP can be released from the
bacterial surface as a soluble enzyme and it is likely that flexibility
in the C-terminal linker plays a role in facilitating this event [6,8].
The bacterial cell wall is peppered with proteins and peptido-
glycan that extend from the surface. The disordered linker
upstream of the LPXTG cell wall-anchoring motif offers greater
degrees of conformational freedom and distance from site of
attachment than a structured region of the same size. If extended,
this region could stretch to beyond the cell envelope dimension of
40–60 nm, however any compaction or additional cell wall interac-
tions may restrict the accessibility of the protease domain. Thus,
the ability to further extend the protease head away from the bac-
terial surface, with a host-induced unwrapping of the tandem
domains could provide an effective mechanism for in situ regula-
tion of protease activity.
Fig. 4. Chemical shift indicators of secondary structure in SpyCEP. 13C secondary chemical shifts of the SpyCEP N- and C-terminal disordered regions. Secondary chemical
shifts are shown for (A) 13Ca (B) 13Cb and (C) 13Ca–13Cb secondary chemical shifts calculated for the N-terminus, and exhibit helical propensity in residues 47–50, 71–82 and
99–107. (D) 13Ca (E) 13Cb and (F) 13Ca–13Cb secondary chemical shifts calculated for the C-terminal linker exhibit helical propensity only from residue 1608.
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communication
Protease-associated (PA) domains are rather enigmatic. First
identified in the subtilisin family of proteases, the finer details of
their roles are unclear, although evidence exists to suggest the
PA domain provides additional substrate specificity outside the
catalytic site [61–64]. However, no structures exist for a protease
PA-substrate complex. In the pyrolysin-like subtilases from tomato
plants the PA domain was shown to perform a role in homo-
dimerization and regulation [63]. While no evidence exists for
dimerization of SpyCEP, the insertion of the PA domain directly
above the catalytic site suggests a role in regulating substrate
access (Fig. 5). An analysis of our structure and other key PA-containing proteases highlights some mobility within the PA
domain that might be important for regulating protease activity.
Surprisingly, the structure of the double mutant described
here, SpyCEP(D151AS617A), is most similar to the wild-type
(PBD: 5XYR) and not to the published structure for the alterna-
tive double mutant (H279A, S617A; PBD: 5XXZ). Significant
structural differences exist between the two double mutants,
and these localise to the PA domain and a neighbouring ß-
hairpin that supports the relative positions of the PA and pro-
tease domains (Fig. 5A). This region is completely disordered
in SpyCEP (H279A, S617A) as native contacts between the cat-
alytic H279 and Q613 at the base of the ß-hairpin are removed
by mutation of the histidine to alanine (Fig. 5A). The differences
in the PA domain conformation are likely driven by the loss in
Fig. 5. PA domains are conformationally adaptable. (A) Pairwise superposition of the structure of the protease and PA domains from SpyCEP(D151A, S617A), with equivalent
region from the published SpyCEP(H279A, S617A) structure (pdb: 5XXZ). (B) Putty representation of SpyCEP(D151A, S617A) D1 and D2 with increasing B-factors indicated by
the diameter of the worm and its color (blue to red). (C) Superposition of the relative orientation of the Protease and PA domains from SpyCEP(D151A, S617A) (cyan) with
representative related subtilase structures C5a, (pdb: 1xf1 and 3eif, orange and green) and curcumisin (pdb: 3vta, purple). (D) Simulations of SpyCEP(D151A, S617A) indicate
mobility of PA domain, protein coloured according to RMSD over the simulation (blue largest, red lowest). (E) The active site (H279 shown in white) is solvent accessible in
starting model (t = 0 ns) however motion of the PA domain coupled with loop motions leads to closure of the active site entrance (snapshot at 35 ns shown). Domains
coloured according to Fig. 1. (F) Superposition of PA domain from SpyCEP(D151A, S617A) (cyan) with the PA domain from the vacuole sorting receptor alone (pdb: 4tjv, gold)
and bound (pdb: 4tjx, dark red) to peptide cargo (green sticks). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of
this article.)
658 S. McKenna et al. / Computational and Structural Biotechnology Journal 18 (2020) 650–660structure of this supporting hairpin, which highlights a potential
allosteric link to the catalytic site. Such allostery suggests inter-
domain communication may play a role in enzyme activation.
Strikingly, in solved structures of proteases with PA domains,
the PA domains generally display higher B-factors than the main
protease structure, suggesting a degree of intrinsic flexibility for
this region. Furthermore, in related structures of subtilases the
relative orientation of PA domains with respect to the main body
of the protease varies significantly (Fig. 5B and C). In light of this,
refinement of our SpyCEP structure by using the PA domain and
the rest of the protein as separate search models for molecular
replacement gave significant improvements in electron density
maps over using the whole SpyCEP structure, and a shift in itsrelative position was observed compared to the published struc-
tures. Taken together, these observations suggest that PA domains
are conformationally mobile, and that this feature is likely to be
important for function. To further investigate the role of PA confor-
mational dynamics we performed molecular dynamics simulations
of SpyCEP (D151A, S617A) and supplemented this with normal
mode analysis (NMA) using the elNémo server to probe low fre-
quency motions [65]. In molecular dynamics the greatest mobility
is observed for the PA domain (Figs. 5D and S4). Inspection of the
residues surrounding the catalytic H279 indicate that motion of
the PA domain would modulate access to the active site (Fig. 5E).
B-factors computed from the mean square atomic displacements
for the slowest 100 normal modes show significantly elevated
S. McKenna et al. / Computational and Structural Biotechnology Journal 18 (2020) 650–660 659values for the PA domain (Fig. S5). This pattern matches those
observed in the experimental B-factors for SpyCEP and other PA-
domain protease structures and suggests mobility is an inherent
feature of PA domain function.
As PA domain peaks are absent from 1H-15N HSQC NMR spectra
of SpyCEP (Fig. 3), PA domain mobility is unlikely to be dynamic on
a fast (sub-microsecond) timescale, unlike motions in the termini.
Instead, it is likely that the PA domain adopts distinct stable con-
formations that can interconvert, perhaps driven by binding to
an interaction partner. This notion is reminiscent of other, unre-
lated PA-containing families of proteins, for example the vacuole
trafficking receptors and E3 ubiquitin ligases [66,67], where the
domains play a role in cargo recruitment, delivery and presenta-
tion. In the only available structure of a PA domain complex, the
PA domain of the vacuole sorting receptor (VSR) from Arabidopsis
thaliana (VSR1PA) undergoes a large rearrangement of its N- and
C-terminal regions upon binding cargo peptide [66]. Cargo binding
induces local conformational changes that propagate allosterically
from the cargo binding loop to the C terminus via a network of resi-
dues in switch (I-IV) loop regions (Fig. 5F). Intriguingly, a crucial
R95 residue that makes numerous contacts with the N terminus
of the cargo peptide is conserved across the wider PA family,
including the bacterial subtilases (Fig. S6) [64]. It is therefore con-
ceivable that the PA domain of SpyCEP recognises the N-terminal
ELR motif in CXC substrates via a similar binding mode and a sub-
sequent conformation change delivers the C-terminal cleavage site
to the catalytic triad.4. Concluding remarks
Structural and functional understanding of the SpyCEP protein
have enabled rational design of a catalytically-inactive mutant
which was herein demonstrated to be an effective protective
immunogen in a mouse challenge model of GAS infection. Exten-
sive structural analyses provided several insights into SpyCEP bio-
logical function and have improved the level of characterization of
this vaccine antigen. In particular, crystal structures of SpyCEP are
strongly indicative of a functional mechanism that involves a sig-
nificant conformational change to modulate the accessibility of
the active site. We propose a model in which the PA domain pro-
vides the initial point for CXCL8 docking, which induces a subse-
quent conformational change for optimal delivery of the C
terminus to an opened active site. Our data facilitate and lend con-
fidence to the development of a protective GAS vaccine using the
existing double mutant SpyCEP(D151A, S617A) antigen. Moreover,
the new molecular details provide the basis for both a deeper
structure-guided approach to design of next-generation SpyCEP
antigens and to the rational design of small-molecule active site
therapeutic protease inhibitors to treat GAS diseases.CRediT authorship contribution statement
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